Abstract
Anti-inflammatory agents are routinely used to treat inflammatory diseases affecting both anterior and/or posterior segments of the eye. Corticosteroids and NSAIDs can be administered either topically onto the ocular surface structures or injected into the eye. However, one of the most important handicaps of ocular treatments is the presence of several anatomical and physiological barriers in the eye that drastically reduce drug access to the target site. The hydrophobicity of anti-inflammatory agents, low drug bioavailability, and the invasiveness of intraocular drug delivery are main reasons to explore the potential application of drug delivery-related technologies to develop new antiinflammatory ocular therapies. This review summarizes conventional anti-inflammatory treatments for ocular diseases and the ongoing research efforts to develop improved drug delivery systems. Micro-size intraocular implants, microparticles, nanoparticles, and liposomes are the preferred delivery systems in study.
Keywords: Anti-inflammatory drugs, corticosteroids, drug delivery, eye disease, nanomedicine, nanoparticles, NSAIDs, ocular drug administration, Ophthalmology, OCULAR ANTI-INFLAMMATORY THERAPY
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents
Volume: 10 Issue: 3
Author(s): Yolanda Diebold, Laura Contreras-Ruiz, Isabel Arranz-Valsero and Laura Garcia-Posadas
Affiliation:
Keywords: Anti-inflammatory drugs, corticosteroids, drug delivery, eye disease, nanomedicine, nanoparticles, NSAIDs, ocular drug administration, Ophthalmology, OCULAR ANTI-INFLAMMATORY THERAPY
Abstract: Anti-inflammatory agents are routinely used to treat inflammatory diseases affecting both anterior and/or posterior segments of the eye. Corticosteroids and NSAIDs can be administered either topically onto the ocular surface structures or injected into the eye. However, one of the most important handicaps of ocular treatments is the presence of several anatomical and physiological barriers in the eye that drastically reduce drug access to the target site. The hydrophobicity of anti-inflammatory agents, low drug bioavailability, and the invasiveness of intraocular drug delivery are main reasons to explore the potential application of drug delivery-related technologies to develop new antiinflammatory ocular therapies. This review summarizes conventional anti-inflammatory treatments for ocular diseases and the ongoing research efforts to develop improved drug delivery systems. Micro-size intraocular implants, microparticles, nanoparticles, and liposomes are the preferred delivery systems in study.
Export Options
About this article
Cite this article as:
Diebold Yolanda, Contreras-Ruiz Laura, Arranz-Valsero Isabel and Garcia-Posadas Laura, Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (3) . https://dx.doi.org/10.2174/1871523011109030203
DOI https://dx.doi.org/10.2174/1871523011109030203 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Delivery to the Back of the Eye Following Topical Administration: An Update on Research and Patenting Activity
Recent Patents on Drug Delivery & Formulation Vascular Endothelial Growth Factor and Angiopoietins in Neurovascular Regeneration and Protection Following Stroke
Current Neurovascular Research Intravitreal Steroids for the Prevention of PVR After Surgery for Retinal Detachment
Current Pharmaceutical Design Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Subthreshold Laser Therapy for Diabetic Macular Edema: Metabolic and Safety Issues
Current Medicinal Chemistry Nanotechnology in Ophthalmic Drug Delivery: A Survey of Recent Developments and Patenting Activity
Recent Patents on Nanomedicine Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry α7 Nicotinic Acetylcholine Receptor Subunit in Angiogenesis and Epithelial to Mesenchymal Transition
Current Drug Targets Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Glucocorticoids: Structure, Signaling and Molecular Mechanisms in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema
Current Molecular Medicine Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design Effect of Immunoglobulin Therapy on Blood Viscosity and potential concerns of Thromboembolism, Especially in Patients with Acute Kawasaki Disease
Recent Patents on Cardiovascular Drug Discovery Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design The Sleeping Beauty Transposon Vector System for Treatment of Rare Genetic Diseases: An Unrealized Hope?
Current Gene Therapy Polymeric Nanoparticles for Ophthalmic Drug Delivery: An Update on Research and Patenting Activity
Recent Patents on Nanomedicine Vascular Changes of the Retina and Choroid in Systemic Lupus Erythematosus: Pathology and Pathogenesis
Current Neurovascular Research Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Role of Non-Coding RNA of Human Platelet in Cardiovascular Disease
Current Medicinal Chemistry Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued)